Abstract
Introduction
Anti-neutrophil cytoplasmic antibodies (ANCAs) are a group of autoantibodies which can be detectable in various autoimmune and/or vasculitic conditions. ANCAs can be detected using direct immunofluorescence method. The primary molecular target is proteinase 3 within the cytoplasm of neutrophils and monocytes for cytoplasmic ANCA (cANCA) and myeloperoxidase (MPO) for perinuclear ANCA (pANCA). Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a complex phenomenon because of an inflammation of small and larger vessels with polymorph infiltration within the vessel walls and leukocytoclasis due to production of autoantibodies to neutrophil cytoplasmic components. It has been demonstrated that ANCAs are able to stimulate neutrophils. In vitro, ANCAs can activate neutrophils primed with tumor necrosis factor-alpha (TNF-α) for the production of reactive oxygen intermediates (ROI), the release of lysosomal enzymes, and the secretion of interleukin-1 [1] [2] [3] . Apart from inducing the activation of neutrophils, ANCAs also activate monocytes and/or endothelial cells [3] [4] [5] . The central mechanism in autoimmunity is the breaking of self-tolerance. Risk factors for breaking self-tolerance to ANCA antigens are genetic factors, drugs, chemical substances and/or infectious agents. A combination of risk factors may be present in patients who develop ANCA. Vascular damage in AAV and/or glomerulonephritis results predominantly from activation of neutrophils when these cells adhere to endothelial cells [6] [7] [8] .
Propylthiouracil (PTU) is an anti-thyroid drug used for the treatment of hyperthyroidism.
Although there are some cases in the literature with p-ANCA positive vasculitis associated with PTU treatment, the pathogenesis of PTU-related vasculitis is still unknown. It has been hypothesized that PTU serves as a MPO substrate for free radical production [9] . It is not clear if ANCA has a direct pathogenic role in the development of PTU-associated vasculitis.
On withdrawal of PTU, clinical improvement was associated with a fall in the ANCA titer [10] . The literature reports 20 to 40 percent of patients treated with PTU for hyperthyroidism become ANCA positive and of these patients, nearly one-fifth develop features consistent with vasculitis [11] [12] [13] [14] .
When drug-induced vasculitis is suspected, quick diagnostic procedures should be carried out therapy for polymicrobial infection from skin ulcers, and it was stopped after 7 days of antibiotic therapy. Simultaneously, it was found that cANCA was positive; thus, the diagnosis of necrotizing vasculitis was also confirmed. Pulse cyclophosphamide immunosuppressive therapy was planned but it could not be initiated because she developed thrombocytopenia.
Her medical condition was deemed unfit for thyroidectomy and thyroid function tests did not confirm euthyroid status. As a result, total thyroidectomy was not performed and deferred until after resolution of thrombocytopenia. During the follow-up period, a plastic and reconstructive surgery specialist was consulted for the patient and remaining necrotic tissues were debrided again. However, despite all surgical measures, a green-colored suppurative layer developed on the surface of leg ulcers. Then, an infectious diseases specialist was reconsulted and her antibiotic therapy regimen was revised and resumed according to the wound culture antibiograms. During this period, her ulcers appeared again in a disseminated fashion. The patient was discussed at a multidisciplinary meeting which included specialists from Internal Medicine, Rheumatology, General Surgery and Endocrinology Departments and concluded with the decision to prepare the patient for a total thyroidectomy immediately in order to protect her from adverse events of the anti-thyroid drugs as soon as possible.
Therapeutic plasmapheresis was not performed due to the lack of required equipment in our hospital. When her medical condition was suitable for having an operation the patient was operated promptly, and methimazole treatment was stopped. Following total thyroidectomy oral levothyroxin replacement therapy was started. In addition to her primary medical intervention, she was given supplemental therapy such as parenteral albumin, erythrocyte transfusion and isotonic fluids, and daily dressing changes. Despite all medical therapeutic interventions, the patient could not be saved and died due to nosocomial pneumonia and septic shock. www.medicinescience.org | Med-Science 651 more than 18 months has been reported to be associated with the development of ANCA [12, 15, 16] . Some studies have even reported an increase in ANCA positivity with longer duration of PTU use [17] . One series revealed an average PTU treatment duration of 37 months prior to development of clinical symptoms such as vasculitis [15] . However, PTUrelated AAV has been reported to occur from a few months to several years of treatment [13] [14] [15] [16] [17] [18] . At the time of admission, our patient had a history of PTU use for approximately 36 months.
In the present case, the patient initially had only cutaneous symptoms without lung or kidney involvement which occurred after 3 years of PTU treatment and showed a rapid progression of clinical manifestations resulting in death. In literature, mostly pANCA/anti-MPO positivity is reported in vasculitis cases associated with PTU use and c-ANCA/PR3 positivity is seen to a lesser extent [12] [13] [14] 19, 20] . It is postulated that PTU acts as a hapten to bind MPO and results in ANCA positivity by stimulating neutrophils [19, 21] . ANCA development is thought to induce vasculitis by initiating vascular injury. Moreover, human MPO and TPO enzymes belong to the same genetic family and share similarity in nucleotide and amino acid sequences [22, 23] . Thus, pANCA positivity can be expected in PTU-associated AAV seen in patients with Graves' disease. However, AAV induced by PTU use had developed in the setting of toxic nodular goiter without Graves' disease in our patient. Thyroid autoantibodies were checked in order to exclude Graves' disease and found negative and thyroid scintigraphy was consistent with toxic nodules with increased activity. This suggested that some other factors might be involved in the pathogenesis of AAV induced by PTU.
Since methimazole and carbimazole have not been shown to behave as haptens, ANCAassociated vasculitis occurs at a reduced incidence in patients treated with these agents compared to PTU [18, 24] . Thus, we immediately switched from PTU to methimazole therapy with the minimum effective dose chosen for the patient. Plasmapheresis was not available in our hospital; so, total thyroidectomy was performed as soon as possible after achieving euthyroid state when general condition of the patient was considered fit for such procedure.
With this approach, our aim was to discontinue antithyroid therapy altogether (also methimazole, even if it was relatively harmless) and keep her away from further antigenic stimulation. Despite switching from PTU to methimazole and achieving some clinical response with steroid therapy, the patient was lost. A contributory cause of her death was Fournier's gangrene which is associated with high mortality per se and this clinical picture worsened the prognosis and adversely affected the clinical course [25] . Her treatment became more challenging due to a number of factors including disseminated, advanced ulcers in the whole body which exposed the patient to additional infections and requirement for debridement and long-term parenteral antibiotic therapy. Additional risks were also present such as susceptibility to potential nosocomial infections associated with long-term hospitalization. Eventually, the patient diagnosed at an advanced stage could not be saved despite all efforts.
Most importantly, cutaneous symptoms of the patient could have been linked with PTU use with appropriate history taking when they first appeared (several months in advance) and PTU treatment could have been withdrawn. Maybe then she could be saved before her clinical manifestations advanced to an irreversible point. Thus, clinicians and particularly dermatologists should be aware of AAV associated with PTU treatment.
Conclusion
While pANCA/MPO positivity is observed in cases of AAV related with PTU use, cANCA positivity may be rarely encountered as in our patient. A distinctive feature of our case was the presence of cutaneous symptoms solely without lung and kidney involvement despite cANCA positivity. During PTU use, physicians should be alert for potential dermal and systemic adverse effects of PTU and PTU treatment must be immediately discontinued at the slightest suspicion.
